The World ADC Awards Judges are handpicked for their longstanding familiarity and deep knowledge of the ADC field.
Jagath Junutula, VP, Cellerant Therapeutics
Dr. Jagath Reddy Junutula joined Cellerant in April 2014 as a Vice President, Antibody Discovery & Development. Prior to joining Cellerant, Jagath was at Genentech for 13 years focusing on oncology drug discovery and development, including discovery and validation of targets for treatment of cancer; design, development and pre-clinical validation of antibody drug conjugates (ADCs); engineering next-generation ADCs; and development of bi-specific antibody/protein based cancer immunotherapeutic platforms for treatment of different types of cancers. He developed a novel THIOMAB technology platform to generate site-specific antibody-drug conjugates (ADCs) to improve the therapeutic utility of antibodies. This technology has widely been accepted as a new standard for the development of therapeutic ADCs. He obtained his PhD in 1997 from the Indian Institute of Science, Bangalore, India, and did post-doctoral research in Germany as an Alexander von Humboldt fellow and at Stanford University. Jagath has authored 60 peer-reviewed publications/patents and has presented his work at numerous international conferences. Jagath serves as an editorial board member of leading antibody therapeutics journal, mAbs.
Greg landes, Independent consultant
Gregory Landes has over 30 years of experience in the biotechnology industry with broad expertise in target discovery and validation, antibody and ADC drug discovery and preclinical development, molecular biology, genetics, genomics, and biochemistry. He currently consults with over a dozen companies in the disciplines described above as well as automation, biosimilars and antibody effector function. In addition, he leads workshops at national antibody conferences in a variety of areas of expertise including antibody effector function and antibody drug conjugates. He has held positions of significant responsibility with major biopharmaceutical companies including Takeda California/Takeda San Francisco (VP Biology/VP Discovery, Research and Preclinical Development, Lexicon Pharmaceuticals (VP, Biotherapeutics), Abgenix (VP, Product Discovery), Genzyme (VP, Genetics and Genomics), and Integrated Genetics ((Senior Scientist, Genetics and DNA Diagnostics). He holds a BA in Chemistry and PhD in Biochemistry from the University of Kansas and was awarded a post-doctoral scholarship from UCLA’s Molecular Biology Institute as well as an NIH post-doctoral award.
Alan rigby, CSO, Synta Pharmaceuticals